Doxorubicin liposomal - Celsion Corporation

Drug Profile

Doxorubicin liposomal - Celsion Corporation

Alternative Names: Liposome encapsulated doxorubicin; LTLD; LTSDEL; Lyso-thermosensitive liposomal doxorubicin; ThermoDox

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Celsion Corporation
  • Developer Brigham and Womens Hospital; Celsion Corporation; Focused Ultrasound Foundation; Harvard Medical School; University of Oxford
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Hepatocellular carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Phase II Breast cancer; Liver metastases
  • Preclinical Brain cancer; Glioblastoma; Pancreatic cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 18 Jan 2017 Celsion receives patent allowance for ThermoDox® in USA and South Korea
  • 16 Dec 2016 Celsion announces intention for a regulatory submission to China Food and Drug Administration (CFDA) for the treatment of Hepatocellular carcinoma
  • 15 Aug 2016 Celsion Corporation announces intention to submit NDA to C FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top